One of the most discussed aspects of healthcare has to be how to balance cost, quality and access. This is especially true when it comes to the pharmaceutical industry, particularly with the rapid growth of and increased focus on highly effective, but highly expensive, specialty drugs. Discussions about these costs are no longer isolated to negotiations between pharmaceutical companies, PBMs and insurers; instead it appears that price and cost are on FDA's radar.
For example, the Oncologic Drugs Advisory Committee ("ODAC") hearing, earlier this month, was not only historic ...
Blog Editors
Recent Updates
- 2024 Update: Regulators Use “Carrots and Sticks” to Incentivize Healthcare Sector Cybersecurity Compliance
- Proposed Minnesota House Bill HF 4206 Would Prohibit Ownership Interests, Operational/Financial Control of Health Care Providers by Private Equity and REITS
- Proposed CA Assembly Bill 3129: Notice & Consent for Private Equity, Hedge Funds Acquiring/Changing Control of Health Care Facilities, Provider Groups
- Update: Alabama Legislature Moves to Shield IVF from “Personhood” Ruling
- Time Runs Out in the Oregon State Senate for HB 4130, but Will Likely Return in 2025